Label: CIFRAZOL capsule

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated January 13, 2017

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Cifrazol is an orally administered prescription Vitamin for the dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D supplementation due to Vitamin D deficiency and other nutritional supplementation.

    Cifrazol should be administered under the supervision of a licensed medical practitioner.

    Vitamin D3 (cholecalciferol) is a white, crystalline powder, very soluble in water, with the following structural formula:

    form

    Each capsule contains:
    Folic Acid: 1mg, Vitamin D3 (Cholecalciferol): 3775IU

    Each capsule contains the following inactive ingredients: Gelatin,Water, Soybean Oil, Yellow Wax, Lecithin,Glycerin, FD&C Red #40, FD&C Yellow #5, Titanium Dioxide.

  • INDICATIONS AND USAGE

    Cifrazol is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.

  • CLINICAL PHARMACOLOGY

    The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

    There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

  • CONTRAINDICATIONS

    This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Cifrazol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

  • WARNINGS AND PRECAUTIONS

    Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits.

    Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

  • ADVERSE REACTIONS

    This medication is generally well tolerated. Notify your doctor if you experience: nausea, loss of appetite, vomiting, stomach cramps, dry mouth, increased thirst, increased urination, muscle or bone pain,headache, weakness, weight loss, dizziness. If you notice other effects not listed above, contact your doctor or pharmacist.

  • DOSAGE AND ADMINISTRATION

    Take one capsule daily or as directed by a physician.

  • HOW SUPPLIED

    Cifrazol capsules are supplied as orange capsules printed with 300 dispensed in HDPE plastic bottles of 30ct.

    NDC 69336-310-30

  • STORAGE AND HANDLING SECTION

    Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place.

    Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

  • OTHER SAFETY INFORMATION

    Reserved for Professional Recommendation

    All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

  • PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

    Rx Only
    Reserved for Professional Recommendation
    All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

    carton

    Manufactured for:

    Sterling Knight Pharmaceuticals, LLC
    Ripley, MS 38663
    Rev. 1114-1

  • INGREDIENTS AND APPEARANCE
    CIFRAZOL 
    cifrazol capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:69336-310
    Route of AdministrationOral
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CHOLECALCIFEROL (UNII: 1C6V77QF41) (CHOLECALCIFEROL - UNII:1C6V77QF41) CHOLECALCIFEROL3775 [iU]
    FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8) FOLIC ACID1 mg
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SOYBEAN OIL (UNII: 241ATL177A)  
    YELLOW WAX (UNII: 2ZA36H0S2V)  
    LECITHIN, SOYBEAN (UNII: 1DI56QDM62)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    FD&C YELLOW NO. 5 (UNII: I753WB2F1M)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    GELATIN (UNII: 2G86QN327L)  
    Product Characteristics
    ColororangeScoreno score
    ShapecapsuleSize22mm
    FlavorImprint Code 300
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69336-310-3030 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product01/10/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other01/10/2017
    Labeler - Sterling Knight Pharmaceuticals,LLC (079556942)